Abstract Details

Title Perspectives on Parkinson's Disease Medications: A Qualitative Study of People with Parkinson's Disease

Topic Movement Disorders

Presentation(s) P14 - Poster Session 14 (11:45 AM-12:45 PM)

Poster/Presentation
Number 5-015

Objective To explore the thoughts, beliefs, and expectations of people with Parkinson’s disease (PwPD) regarding their Parkinson’s disease (PD) medications.

Background Few studies investigate the factors that inform the impact of PD medications on individuals’ lives. This qualitative study aims to better understand PwPD’s experiences with and perspectives on their medications.

Design/Methods PwPD treated with PD medications at five movement disorder clinics in five states across the United States were recruited to participate in semi-structured interviews (SSIs) and focus groups (FGs). Interview and moderator guides developed to explore participants’ experiences with PD medication were utilized. Inclusion criteria consisted of confirmed PD diagnosis, history of taking medications for PD, aged ≥18 years, and ability to consent and participate. SSI and FG transcripts were analyzed via grounded theory methodology to identify primary themes and subthemes.

Results Twenty PwPD (8 females/12 males; aged 48-80 years) participated in one-hour telephone SSIs and 32 (16 females/16 males; aged 57-86 years) participated in one-hour online FGs. Four primary themes (subthemes in parentheses) emerged regarding medications for PD: (1) effectiveness (effectiveness uncertainty, expectation realignment), (2) side effects (tolerating side effects, discerning side effects vs disease progression), (3) timing challenges (dosage timing, off-times), and (4) desires (more options, therapy advancement). Participants were uncertain whether they were experiencing the full benefits of their medications and unsure of whether their symptoms were medication side effects or signs of disease progression. High dosing frequency is especially taxing on PwPD, and participants expressed a desire for longer-lasting medications and more therapeutic options.

Conclusions This study identified four core dimensions of PD medications from the perspective of PwPD. Results indicate the need for enhanced communication between providers and patients regarding PD medication to reduce uncertainties around symptom burden, and continued efforts to develop and advance PD treatments.

Authors/Disclosures
Steve Arcona, PhD (Cerevel) PRESENTER	Dr. Arcona has received personal compensation for serving as an employee of Cerevel. Dr. Arcona has stock in Cerevel.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Rahul Sasane, PhD (Cerevel Therapeutics)	Dr. Sasane has received personal compensation for serving as an employee of Cerevel Therapeutics. Dr. Sasane has stock in Cerevel Therapeutics.
Melissa Armstrong, MD, MSc, FAAN, FAAN (UF Department of Neurology)	The institution of Dr. Armstrong has received research support from National Institutes of Health. The institution of Dr. Armstrong has received research support from Florida Department of Health. The institution of Dr. Armstrong has received research support from Lewy Body Dementia Association. The institution of Dr. Armstrong has received research support from The Michael J. Fox Foundation. Dr. Armstrong has received personal compensation in the range of $5,000-$9,999 for serving as a DSMB member with Alzheimer's Clinical Trials Consortium. Dr. Armstrong has received personal compensation in the range of $5,000-$9,999 for serving as a DSMB member with Alzheimer's Disease Cooperative Study. Dr. Armstrong has received personal compensation in the range of $500-$4,999 for serving as a DSMB member with National Institutes of Health. Dr. Armstrong has a non-compensated relationship as a Member, Scientific Advisory Council with Lewy Body Dementia Association that is relevant to AAN interests or activities.
Jeanne Feuerstein, MD (University of Colorado School of Medicine)	Dr. Feuerstein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jazz Pharmaceutical. The institution of Dr. Feuerstein has received research support from Mowry Fund Grant. The institution of Dr. Feuerstein has received research support from Davis Phinney. Dr. Feuerstein has received research support from MJFF - Write Now Initiative. Dr. Feuerstein has received personal compensation in the range of $500-$4,999 for serving as a Parkinson's Expert for Legal Case with Keating Wagner Palidori. Dr. Feuerstein has received personal compensation in the range of $100,000-$499,999 for serving as a Attending Neurologist with VAMC. Dr. Feuerstein has received personal compensation in the range of $100,000-$499,999 for serving as a Assistant Professor of Neurology with University of Colorado.
Holly A. Shill, MD, FAAN (Barrow Neurology Clinics)	Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage Biogen. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for KeifeRx. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Praxis Precision Medicine. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Fasikl Inc. Dr. Shill has received personal compensation in the range of $0-$499 for serving as a Consultant for Boston Scientific. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe Pharma America.
Lauren S. Talman, MD	Dr. Talman has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Oregon Federal Public Defenders Office. Dr. Talman has received personal compensation in the range of $500-$4,999 for serving as a panelist with HDSA.
Sneha Mantri, MD, MS, FAAN	Dr. Mantri has received personal compensation for serving as an employee of Parkinson's Foundation. Dr. Mantri has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. The institution of Dr. Mantri has received research support from The Michael J Fox Foundation for Parkinson Research.

��ɫ��

��ɫ��